2-(chlorocarbonyl)-6-methoxyphenyl acetate | 58778-45-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 2-(chlorocarbonyl)-6-methoxyphenyl acetate
• 英文别名: 2-acetoxy-3-methoxy-benzoyl chloride；3-Methoxy-2-acetoxy-benzoesaeure-chlorid；2-Acetoxy-3-methoxybenzoyl chloride；(2-carbonochloridoyl-6-methoxyphenyl) acetate
• CAS: 58778-45-3
• 化学式: C₁₀H₉ClO₄
• 分子量: 228.632
• InChiKey: CWSBDVGMKLPIDB-UHFFFAOYSA-N

物化性质

• 沸点：
  306.2±27.0 °C(Predicted)
• 密度：
  1.288±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(chlorocarbonyl)-6-methoxyphenyl acetate 在 吡啶 、 甲醇 、 氨 作用下， 以 二氯甲烷 为溶剂， 反应 3.25h， 生成 N-[(2R,3R,3aS,9aR)-2-(6-Amino-purin-9-yl)-5,5,7,7-tetraisopropyl-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-3-yl]-2-hydroxy-3-methoxy-benzamide
  参考文献：
  名称：

  Selective Tight Binding Inhibitors of Trypanosomal Glyceraldehyde-3-phosphate Dehydrogenase via Structure-Based Drug Design

  摘要：

  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from the sleeping sickness parasite Trypanosoma brucei is a rational target for anti-trypanosomatid drug design because glycolysis provides virtually all of the energy for the bloodstream form of this parasite. Glycolysis is also an important source of energy for other pathogenic parasites including Trypanosoma cruzi and Leishmania mexicana. The current study is a continuation of our efforts to use the X-ray structures of T. brucei and L. mexicana GAPDHs containing bound NAD(+) to design adenosine analogues that bind tightly to the enzyme pocket that accommodates the adenosyl moiety of NAD(+). The goal was to improve the affinity, selectivity, and solubility of previously reported 2'-deoxy-2'-(3-methoxybenzamido)adenosine (1). It was found that introduction of hydroxyl functions on the benzamido ring increases solubility without significantly affecting enzyme inhibition. Modifications at the previously unexploited N-6-position of the purine not only lead to a substantial increase in inhibitor potency but are also compatible with the 2'-benzamido moiety of the sugar. For N-6-substituted adenosines, two successive rounds of modeling and screening provided a 330-fold gain in affinity versus that of adenosine. The combination of N-6- and 2'-substitutions produced significantly improved inhibitors. N-6-Benzyl (9a) and N-6-2-methylbenzyl (9b) derivatives of 1 display IC50 values against L. mexicana GAPDH of 16 and 4 mu M, respectively (3100- and 12500-fold more potent than adenosine). The adenosine analogues did not inhibit human GAPDH. These studies underscore the usefulness of structure-based drug design for generating potent and species-selective enzyme inhibitors of medicinal importance starting from a weakly binding lead compound.

  DOI：

  10.1021/jm9802620
• 作为产物：
  描述：

  3-甲氧基水杨酸 在 吡啶 、 氯化亚砜 、 硫酸 、 溶剂黄146 作用下， 以 乙醚 为溶剂， 反应 1.0h， 生成 2-(chlorocarbonyl)-6-methoxyphenyl acetate
  参考文献：
  名称：

  新型噻唑类化合物及其制备方法和用途

  摘要：

  一种新型噻唑类化合物及其前药、药学上可接受的盐、晶体和它们的药物组合物、以及它们的制备方法和用途。所述化合物不但能够显著提高生物活性，而且能有效地减少被糖甙化而失去生物活性，显著提高有效药物的暴露量，扩大了其临床应用。

  公开号：

  CN115197164A

文献信息

• 噻唑类化合物及其制备方法和用途
  申请人：杜心赟

  公开号：CN113277994A

  公开（公告）日：2021-08-20

  本发明涉及噻唑类化合物及其制备方法和用途，属于药物化学领域。其具有如下结构通式，该类化合物或其前药或它们药学上可接受的盐不但能够显著提高生物活性，而且能有效地减少被糖甙化而失去生物活性，显著提高有效药物的暴露量，可用于制备预防或治疗肝纤维化药物、预防或治疗病毒性感冒药物、治疗阿兹海默症和帕金森病药物等，扩大了其临床应用。
• Substituted 2-amino chromones and process for the preparation thereof
  申请人：Warner-Lambert Company

  公开号：US03932466A1

  公开（公告）日：1976-01-13

  This invention relates to substituted 2-amino chromones of the general structure I: ##SPC1## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 may be hydrogen, hydroxy, lower alkyl or lower alkoxy of 1-6 carbon atoms, halogen such as chloro or bromo, or aryl such as phenyl, and X may be cyano or carboxamido. Two novel procedures for preparing substituted 2-amino chromones having the Formula I, starting with salicylic acid or substituted salicylic acid, are described. The compounds of this invention are active in the prevention of allergic and asthmatic reactions in mammals.

  本发明涉及一般结构I的取代2-氨基香豆素：##SPC1## 其中R.sub.1、R.sub.2、R.sub.3和R.sub.4可以是氢、羟基、1-6个碳原子的低烷基或低烷氧基、氯或溴等卤素或苯基，X可以是氰基或羧酰胺基。本文描述了两种用水杨酸或取代水杨酸为起始物制备具有式I的取代2-氨基香豆素的新方法。本发明化合物在预防哺乳动物过敏和哮喘反应方面具有活性。
• N-benzoyl amino acid derivatives pharmaceutical compositions containing
  申请人：Gyogyszerkutato Intezet KFT

  公开号：US05705529A1

  公开（公告）日：1998-01-06

  The invention relates to novel N-benzoylamino acid derivatives of the general formula (I), ##STR1## wherein R.sup.1 and R.sup.2, which are the same or different, stand for a hydroxyl group optionally bearing an acetyl group; or a C.sub.1-6 alkoxy group optionally substituted by a phenyl group; n means an integer from 2 to 15 as well as their tautomers, racemates and optically active individual (pure) isomers or mixtures thereof and the salts of these compounds and pharmaceutical compositions containing these compounds. The invention relates also to a process for the preparation of compounds of the general formula (I). The compounds of general formula (I) inhibit the peroxidation of lipids and therefore, they are expected to be useful for the treatment of diseases being in an indirect or direct connection with pathological oxidation processes, chiefly for the treatment and/or prevention of ischaemic and reperfusion tissue injuries, inflammatory reactions, atherosclerosis, various degenerative neurological disorders as well as for delaying the natural process of the ageing of cells.

  本发明涉及一种新颖的N-苯甲酰氨基酸衍生物，其一般式为（I）：##STR1## 其中R1和R2相同或不同，代表一个氢氧基，可选地带有乙酰基；或一个C.sub.1-6烷氧基，可选地被苯基取代；n代表2至15的整数，以及它们的互变异构体、外消旋体和光学活性单体（纯异构体）或其混合物以及这些化合物的盐和含有这些化合物的药物组成物。本发明还涉及一种制备一般式（I）化合物的方法。一般式（I）化合物抑制脂质的过氧化作用，因此，它们预计可用于治疗与病理氧化过程有间接或直接联系的疾病，主要用于治疗和/或预防缺血和再灌注组织损伤、炎症反应、动脉粥样硬化、各种退行性神经疾病以及延缓细胞自然衰老过程。
• N-benzoylamino acid derivatives, pharmaceutical compositions containing
  申请人：Gyogyszerkutato Intezet KFT

  公开号：US05854250A1

  公开（公告）日：1998-12-29

  An N-benzoylamino acid compound of the formula (I), ##STR1## wherein R.sup.3 is an NR.sup.4 R.sup.5 group where R.sup.4 and R.sup.5 which are the same or different are selected from the group consisting of hydrogen, a hydroxyl group, a C.sub.1-12 alkyl group, a C.sub.1-4 alkyl group substituted by a hydroxyl group and a C.sub.1-4 alkyl group substituted by an amino group; R.sup.4 and R.sup.5 when taken together with the adjacent nitrogen form a substituted or unsubstituted 5- or 6-membered heterocyclic group, a 5- or 6-membered heterocyclic group containing an additional nitrogen atom, a 5- or 6-membered heterocyclic group containing an additional nitrogen atom and being substituted by an oxo group, a phenyl-substituted C.sub.1-4 alkyl group or C.sub.3-5 alkenyl group; with the proviso that when the heterocyclic group is piperazine, this heterocyclic group may also be substituted by a diaminopyrimidinyl or di(pyrrolidino)-pyrimidinyl group; n is an integer from 2 to 15; and their tautomers, racemates and the pure optically active individual isomers or mixtures thereof, and a pharmaceutically acceptable salt thereof is described. These compounds are useful for the treatment of patients suffering from disorders being in an indirect or direct connection with pathological oxidation processes occurring in the organism, particularly ischaemic and reperfusion tissue injuries, inflammations, atherosclerosis, or degenerative neurological disorders.

  化合物(I)的N-苯甲酰氨基酸，其公式为：##STR1##其中，R.sup.3是NR.sup.4R.sup.5基团，其中R.sup.4和R.sup.5相同或不同，选择自氢、羟基、C.sub.1-12烷基、被羟基取代的C.sub.1-4烷基或被氨基取代的C.sub.1-4烷基的群；当R.sup.4和R.sup.5与相邻的氮一起形成取代或未取代的5-或6-成员杂环基团、含有额外氮原子的5-或6-成员杂环基团、含有额外氮原子且被氧代基取代的5-或6-成员杂环基团、苯基取代的C.sub.1-4烷基或C.sub.3-5烯基基团时，当杂环基团为哌嗪时，此杂环基团也可以被二氨基嘧啶基团或二(吡咯烷基)-嘧啶基团取代；n为2到15的整数；它们的互变异构体、外消旋体和纯光学活性的单一异构体或其混合物以及其药学上可接受的盐也被描述。这些化合物对于治疗患有与机体中发生的病理氧化过程间接或直接相关的疾病的患者特别有用，包括缺血和再灌注组织损伤、炎症、动脉硬化或变性神经疾病。
• Synthesis and antimicrobial evaluation of new benzofuran derivatives
  作者：Xizhen Jiang、Wenlu Liu、Wei Zhang、Faqin Jiang、Zhe Gao、Hao Zhuang、Lei Fu

  DOI：10.1016/j.ejmech.2011.04.053

  日期：2011.8

  Thirteen compounds, based on benzofuran skeleton bearing aryl substituents at its C-3 position through methanone linker, were synthesized and screened for their antibacterial and antifungal activities against four bacteria Escherichia coli, Staphylococcus aureus, Methicillin-resistant S. aureus, Bacillus sub fills, and a fungus Candida albicans. Four hydrophobic benzofuran analogs were found to exhibit favorable antibacterial activities (MIC80 = 0.39-3.12 mu g/mL), which were better than the control drugs. (C) 2011 Elsevier Masson SAS. All rights reserved.